[Holliday Junction-recognizing Protein is a Potential Predictive and Prognostic Biomarker for Kidney Renal Clear Cell Carcinoma]

Overview

Journal Nan Fang Yi Ke Da Xue Xue Bao

Specialty General Medicine

Date 2024 Dec 26

PMID 39725623

Authors

Huahua Zhang

Qingyin Ta

Yun Feng

Jiming Han

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate the role of Holliday cross-recognition protein (HJURP) in tumorigenesis, progression, and immunotherapy responses.

Methods: Bioinformatics approaches were used to analyze the expression level of in various cancers and its association with prognosis, clinical stage, and immune cell infiltration using TCGA, GTEx, SangerBox and TIMER 2.0 databases. LinkedOmics database was employed to investigate -related genes and their potential functions in kidney renal clear cell carcinoma (KIRC). The expression of in KIRC samples was examined with immunohistochemistry, Western blotting and qRT-PCR, and the effect of silencing on cell proliferation and migration was tested in cultured KIRC cells.

Results: was highly expressed in 26 cancers with negative correlations with the patients' survival outcomes in 5 cancers including KIRC (<0.05). expression levels was strongly correlated with clinical stages and immune cell infiltration in the tumors. In KIRC, expression was significantly elevated (<0.0001) and showed a positive correlation with TNM stage (<0.05), overall stage (<0.01) and immune cell infiltration. Gene Ontology (GO) functional analysis showed that is predominantly enriched in biological processes such as biological regulation and metabolic processes. Concerning cellular components, is primarily localized to the cell membrane and nucleus. In terms of molecular functions, it is chiefly enriched in activities related to protein binding and ion binding. was highly expressed in both clinical KIRC tissues and KIRC cell lines (<0.001). In cultured KIRC cells, silencing of significantly inhibited cell proliferation and migration abilities.

Conclusions: may serves as an indicator of prognosis and immunotherapy response of KIRC, and its high expression enhances malignant behaviors of KIRC cells.

References

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2024; 1(3):e36. PMC: 10989974. DOI: 10.1002/imt2.36. View

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

Koike Y, Yin C, Sato Y, Nagano Y, Yamamoto A, Kitajima T . TPX2 is a prognostic marker and promotes cell proliferation in neuroblastoma. Oncol Lett. 2022; 23(4):136. PMC: 8907931. DOI: 10.3892/ol.2022.13256. View

Gu Y, Li J, Guo D, Chen B, Liu P, Xiao Y . Identification of 13 Key Genes Correlated With Progression and Prognosis in Hepatocellular Carcinoma by Weighted Gene Co-expression Network Analysis. Front Genet. 2020; 11:153. PMC: 7059753. DOI: 10.3389/fgene.2020.00153. View

Li L, Jiang P, Hu W, Zou F, Li M, Rao T . AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2. J Transl Med. 2024; 22(1):295. PMC: 10956193. DOI: 10.1186/s12967-024-05099-6. View

Telloni S . Tumor Staging and Grading: A Primer. Methods Mol Biol. 2017; 1606:1-17. DOI: 10.1007/978-1-4939-6990-6_1. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

Kato T, Sato N, Hayama S, Yamabuki T, Ito T, Miyamoto M . Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 2007; 67(18):8544-53. DOI: 10.1158/0008-5472.CAN-07-1307. View

10.

Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-9. PMC: 4348009. DOI: 10.1056/NEJMoa1411087. View

11.

Xie J, Wang B, Luo W, Li C, Jia X . Upregulation of KIF18B facilitates malignant phenotype of esophageal squamous cell carcinoma by activating CDCA8/mTORC1 pathway. J Clin Lab Anal. 2022; 36(10):e24633. PMC: 9550975. DOI: 10.1002/jcla.24633. View

12.

Wang L, Qu J, Liang Y, Zhao D, Rehman F, Qin K . Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis. Thorac Cancer. 2020; 11(4):851-866. PMC: 7113067. DOI: 10.1111/1759-7714.13298. View

13.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

14.

Li L, Yuan Q, Chu Y, Jiang H, Zhao J, Su Q . Advances in holliday junction recognition protein (HJURP): Structure, molecular functions, and roles in cancer. Front Cell Dev Biol. 2023; 11:1106638. PMC: 10070699. DOI: 10.3389/fcell.2023.1106638. View

15.

Yang Y, Yuan J, Liu Z, Cao W, Liu P . The expression, clinical relevance, and prognostic significance of HJURP in cholangiocarcinoma. Front Oncol. 2022; 12:972550. PMC: 9366246. DOI: 10.3389/fonc.2022.972550. View

16.

Luo D, Liao S, Liu Y, Lin Y, Li Y, Liao X . Holliday Cross-Recognition Protein : Association With the Tumor Microenvironment in Hepatocellular Carcinoma and With Patient Prognosis. Pathol Oncol Res. 2022; 28:1610506. PMC: 9248293. DOI: 10.3389/pore.2022.1610506. View

17.

Robert C, Ribas A, Wolchok J, Hodi F, Hamid O, Kefford R . Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384(9948):1109-17. DOI: 10.1016/S0140-6736(14)60958-2. View

18.

Wang C, Li X, Shi P, Ding H, Liu Y, Li T . Holliday junction recognition protein promotes pancreatic cancer growth and metastasis via modulation of the MDM2/p53 signaling. Cell Death Dis. 2020; 11(5):386. PMC: 7242411. DOI: 10.1038/s41419-020-2595-9. View

19.

Hu Z, Huang G, Sadanandam A, Gu S, Lenburg M, Pai M . The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res. 2010; 12(2):R18. PMC: 2879562. DOI: 10.1186/bcr2487. View

20.

Zhang F, Yuan D, Song J, Chen W, Wang W, Zhu G . HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration. Int Immunopharmacol. 2021; 99:107899. DOI: 10.1016/j.intimp.2021.107899. View